Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Y-mAbs Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: YMAB has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: YMAB exceeded the US Biotechs industry which returned 32.4% over the past year.
Return vs Market: YMAB exceeded the US Market which returned 16.4% over the past year.
Price Volatility Vs. Market
How volatile is Y-mAbs Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
2 months ago | Simply Wall StThis Insider Has Just Sold Shares In Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
3 months ago | Simply Wall StHow Much Are Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insiders Taking Off The Table?
Is Y-mAbs Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate YMAB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate YMAB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: YMAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: YMAB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate YMAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: YMAB is overvalued based on its PB Ratio (11x) compared to the US Biotechs industry average (3.4x).
How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YMAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: YMAB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: YMAB's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if YMAB's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if YMAB's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YMAB is forecast to be unprofitable in 3 years.
How has Y-mAbs Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YMAB is currently unprofitable.
Growing Profit Margin: YMAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 53% per year.
Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).
Return on Equity
High ROE: YMAB has a negative Return on Equity (-77.82%), as it is currently unprofitable.
How is Y-mAbs Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: YMAB's short term assets ($163.3M) exceed its short term liabilities ($15.7M).
Long Term Liabilities: YMAB's short term assets ($163.3M) exceed its long term liabilities ($5.6M).
Debt to Equity History and Analysis
Debt Level: YMAB is debt free.
Reducing Debt: YMAB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: YMAB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 55.2% each year
What is Y-mAbs Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YMAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of YMAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Claus Møller San Pedro (58 yo)
Dr. Claus Juan Møller San Pedro, M.D., Ph.D. has been Chief Executive Officer of Y-mAbs Therapeutics, Inc. since June 2015 and serves as its Director. Dr. Møller was the founder of Azanta A/S, or Azanta, a ...
CEO Compensation Analysis
Compensation vs Market: Claus's total compensation ($USD967.50K) is below average for companies of similar size in the US market ($USD4.53M).
Compensation vs Earnings: Claus's compensation has been consistent with company performance over the past year.
|CEO & Director||5.17yrs||US$967.50k||no data|
|Executive VP||5.17yrs||US$608.35k||0.65% |
|Senior VP & COO||2.75yrs||no data||no data|
|Senior VP & Head of Technical Operations||4.58yrs||no data||no data|
|Senior VP & Chief Scientific Officer||0.58yr||no data||no data|
|Senior VP & Chief Commercial Officer||0.58yr||no data||no data|
|Senior VP & Chief Medical Officer||0.58yr||no data||no data|
Experienced Management: YMAB's management team is considered experienced (3.7 years average tenure).
|CEO & Director||5.17yrs||US$967.50k||no data|
|Independent Director||2.75yrs||US$236.42k||0.093% |
|Independent Director||2.67yrs||US$243.62k||0.093% |
|Independent Director||2.75yrs||US$231.54k||0.037% |
|Director||0.17yr||no data||no data|
|Independent Director||1.67yrs||US$230.84k||0.071% |
Experienced Board: YMAB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: YMAB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17%.
Y-mAbs Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Y-mAbs Therapeutics, Inc.
- Ticker: YMAB
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.601b
- Shares outstanding: 40.01m
- Website: https://www.ymabs.com
Number of Employees
- Y-mAbs Therapeutics, Inc.
- 230 Park Avenue
- Suite 3350
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|YMAB||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 2018|
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United S ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/11 00:16|
|End of Day Share Price||2020/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.